Report of Foreign Issuer (6-k)
October 15 2019 - 12:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October,
2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
Chief
Executive Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
202.000
|
£ 17.1200
|
707.000
|
£ 17.1200
|
704.000
|
£ 17.1200
|
202.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
1815.000
£ 17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R Connor
|
b)
|
Position/status
|
President, Global Vaccines
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
105.000
|
£
17.1200
|
149.000
|
£
17.1200
|
184.000
|
£
17.1200
|
105.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
543.000
£ 17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
66.000
|
£ 17.1200
|
78.000
|
£ 17.1200
|
77.000
|
£ 17.1200
|
66.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
287.000
£ 17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr L Miels
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
142.000
|
£ 17.1200
|
196.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
338.000
£ 17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
83.000
|
£
17.1200
|
145.000
|
£
17.1200
|
174.000
|
£
17.1200
|
83.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
485.000
£ 17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R Simard
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
63.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P Thomson
|
b)
|
Position/status
|
President,
Global Affairs
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
79.000
|
£
17.1200
|
98.000
|
£
17.1200
|
102.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
279.000
£
17.1200
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr B McNamara
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
75.000
|
$
42.2500
|
74.000
|
$
42.2500
|
69.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
218.000
$
42.2500
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr H Barron
|
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
413.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr J Ford
|
b)
|
Position/status
|
SVP and
General Counsel
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
35.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms K Terrell
|
b)
|
Position/status
|
Chief
Digital & Technology Officer
|
c)
|
Initial
notification/amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
25.000
|
$
42.2500
|
87.000
|
d)
|
Aggregated
information
Aggregated volume
Price
|
112.000
$
42.2500
|
e)
|
Date
of the transaction
|
2019-10-14
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
15, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024